{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T06:41:39Z","timestamp":1648881699264},"reference-count":25,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T00:00:00Z","timestamp":1442534400000},"content-version":"unspecified","delay-in-days":7322,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[1995,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Since some years it has become evident that objective disturbances can be found in patients suffering from personality disorders. Research findings from earlier date already demonstrated low levels of 5-hydroxyindoleacetic acid in the cerebrospinal fluid, especially in patients with personality disorders, under exclusion of depressive features. Furthermore, data have been collected on the correlation between a hyposerotonergic state and disturbances in aggression and impulse control in a variety of syndromes such as automutilation, bulimia nervosa, suicide attempts and various states of drug abuse.<\/jats:p><jats:p>However, psychopharmacological research in personality disorders is rare and to date mainly patients with borderline and schizotypical personality disorders have been studied. It is quite remarkable for this area to find more review articles than original contributions based on the results of clinical trials. A great variety of recommendations for pharmacotherapy in these patients exists in literature, among which treatment with carbamazepine, lithium, low-dose neuroleptics, tricyclic antidepressants and serotonin uptake inhibitors. In this article we will analyze the research methodology and the results of clinical trials forming the base for pharmacotherapeutic treatment recommendations.<\/jats:p><jats:p>Only the results of well-controlled studies will be reviewed.<\/jats:p>","DOI":"10.1017\/s0924270800037388","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T05:18:05Z","timestamp":1469510285000},"page":"80-83","update-policy":"http:\/\/dx.doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapeutical treatment of personality disorders"],"prefix":"10.1017","volume":"7","author":[{"given":"J.M. Keppel","family":"Hesselink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2015,9,18]]},"reference":[{"key":"S0924270800037388_ref020","first-page":"333","article-title":"Haloperidol vs. fenelzine in continuation therapy of borderline disorder","volume":"29","author":"Cornelius","year":"1993","journal-title":"Psychopharm Bull"},{"key":"S0924270800037388_ref023","volume-title":"Serotonin 1A receptors in depression and anxiety","author":"Stahl","year":"1992"},{"key":"S0924270800037388_ref015","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1986.01800070081010"},{"key":"S0924270800037388_ref013","first-page":"864","article-title":"Management of borderline personality disorders","volume":"ii","year":"1986","journal-title":"The Lancet"},{"key":"S0924270800037388_ref007","first-page":"524","article-title":"Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression","volume":"25","author":"Parsons","year":"1989","journal-title":"Psychopharm Bull"},{"key":"S0924270800037388_ref006","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1176\/ajp.142.3.277","article-title":"The interface between borderline personality disorder and affective disorder","volume":"142","author":"Gunderson","year":"1985","journal-title":"Am J Psychiat"},{"key":"S0924270800037388_ref008","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psychotherapy.1984.38.2.190"},{"key":"S0924270800037388_ref002","volume-title":"Diagnostic and statistical manual of mental disorders","year":"1980"},{"key":"S0924270800037388_ref016","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198908000-00002"},{"key":"S0924270800037388_ref021","doi-asserted-by":"publisher","DOI":"10.1002\/depr.3050010309"},{"key":"S0924270800037388_ref005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1176\/ajp.149.9.1228","article-title":"The relationship between personality and DSM-III axis I disorders in the population: results from an epidemiological survey","volume":"149","author":"Nestadt","year":"1992","journal-title":"Am J Psychiat"},{"key":"S0924270800037388_ref003","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.161.2.167"},{"key":"S0924270800037388_ref019","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1176\/ajp.150.12.1843","article-title":"Continuation pharmacotherapy of borderline personality disorder with haloperidol and fenelzine","volume":"150","author":"Cornelius","year":"1993","journal-title":"Am J Psychiat"},{"key":"S0924270800037388_ref010","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.108.8.585"},{"key":"S0924270800037388_ref009","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.108.8.579"},{"key":"S0924270800037388_ref017","first-page":"1603","article-title":"Paradoxical effects of amitriptyline on borderline patients","author":"Soloff","year":"1986","journal-title":"Am J Psychiat"},{"key":"S0924270800037388_ref011","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1986.01800070081010"},{"key":"S0924270800037388_ref001","volume-title":"Beeiden in de mist. De geschiedenis van de neurologie in capita selecta","author":"Keppel Hesselink","year":"1994"},{"key":"S0924270800037388_ref014","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(81)90024-X"},{"key":"S0924270800037388_ref018","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1993.01820170055007"},{"key":"S0924270800037388_ref024","first-page":"55","volume-title":"Serotonin 1A receptors in depression and anxiety","author":"De Vrij","year":"1992"},{"key":"S0924270800037388_ref025","doi-asserted-by":"publisher","DOI":"10.1007\/BF02247369"},{"key":"S0924270800037388_ref012","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1986.01800070070009"},{"key":"S0924270800037388_ref022","first-page":"175","article-title":"Een nieuwe klasse farmaca: de azapironen","volume":"18","author":"Keppel Hesselink","year":"1993","journal-title":"TGO\/JDR"},{"key":"S0924270800037388_ref004","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800260015002"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270800037388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T20:51:43Z","timestamp":1557780703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270800037388\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,9]]}},"alternative-id":["S0924270800037388"],"URL":"https:\/\/doi.org\/10.1017\/s0924270800037388","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,9]]},"assertion":[{"value":"Copyright \u00a9 Scandinavian College of Neuropsychopharmacology 1995","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}